Blog

Early Trial Results Show Potential for CAR T-Cell Therapy in Head and Neck Cancer – Targeted Oncology


Targeted Oncology

Early Trial Results Show Potential for CAR T-Cell Therapy in Head and Neck Cancer
Targeted Oncology
Beyond hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapy could also potentially be effective in solid tumors, such as head and neck cancer, according to early results of a clinical trial presented at the 2017 AACR Annual Meeting.

2017-04-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.